Independent Associations of Thyroid-Related Hormones with Hepatic Steatosis and Insulin Resistance in Euthyroid Overweight/Obese Chinese Adults

Danyan Ma
   Xiamen University

Jinyang Zeng
   First Affiliated Hospital of Xiamen University

Bingkun Huang
   First Affiliated Hospital of Xiamen University

Fangfang Yan
   First Affiliated Hospital of Xiamen University

Jiawen Ye
   Fujian Medical University

Yun Chen
   Fujian Medical University

Xiying Zeng
   Fujian Medical University

Xin Zheng
   First Affiliated Hospital of Xiamen University

Fangsen Xiao
   First Affiliated Hospital of Xiamen University

Mingzhu Lin
   First Affiliated Hospital of Xiamen University

Changqin Liu (✉ liuchangqin@xmu.edu.cn)
   First Affiliated Hospital of Xiamen University

Zhibin Li
   First Affiliated Hospital of Xiamen University

Research Article

Keywords: hepatic steatosis, insulin resistance, free triiodothyronine (FT3), controlled attenuation parameter (CAP), fatty liver index (FLI)
Abstract

**Purpose:** The aim of the study is to explore the independent association of free triiodothyronine (FT3), free thyroxine (FT4) and thyroid stimulating hormone (TSH) with hepatic steatosis and insulin resistance.

**Methods:** A cross-sectional study of 88 overweight/obese adults who underwent anthropometric measurements (BMI, waist circumference (WC) and waist-to-height ratio (WHtR)), hepatic steatosis assessment (FibroScan) and thyroid-related hormones tests was conducted from 2018 to 2020 in Xiamen, China.

**Results:** Subjects with increasing tertiles of FT3 showed significantly higher levels of controlled attenuation parameter (CAP) ((295.4±44.1, 290.1 ± 68.2 and 331.7 ± 43.6 (dB/m) for tertile 1-3, respectively, p=0.007) and fatty liver index (FLI) score (47.7 (33.9-60.8), 61.5 (45.1-88.9) and 90.5 (84.5-94.8), respectively, p<0.001). FT3 significantly and positively correlated with obesity index (BMI, WC, and WHtR), homeostatic model assessment of insulin resistance (HOMA-IR) and hepatic steatosis (CAP and FLI). Multivariable linear regression analyses with adjustment for potential confounding factors showed FT3 was independently associated with BMI (regression coefficient ($\beta$ (95%CI): 0.024(0.004-0.043), p=0.020), HOMA-IR ($\beta$ (95%CI): 0.091(0.007-0.174), p=0.034), CAP ($\beta$ (95%CI): 25.45(2.59-48.31), p=0.030) and FLI ($\beta$ (95%CI): 0.121(0.049-0.194), p=0.001). Neither FT4 nor TSH was significantly associated with any indicators of obesity, insulin resistance or hepatic steatosis.

**Conclusions:** Increased FT3, but not FT4 or TSH, was independently associated with higher risks of hepatic steatosis and insulin resistance in euthyroid overweight/obese Chinese adults.

**Trial registration:** Registration is not applicable for our study.

Introduction

Obesity is a worldwide health problem which leads to a series of metabolic disorders via mechanisms of insulin resistance. Nonalcoholic fatty liver disease (NAFLD) as one of metabolic disorders ranges from simple steatosis to nonalcoholic steatohepatitis with fibrosis, which will eventually develop into cirrhosis and hepatocellular carcinoma and is closely related to extrahepatic complication such as dyslipidemia, cardiovascular disease, chronic kidney disease, obstructive sleep apnea syndrome and type 2 diabetes (T2D)[1]. Studies have shown that the prevalence of NAFLD in Asia is around 25%[2], and the value will be higher in obese people[3]. Besides, dysfunctional adipose tissue in obese people is closely related to inflammation and insulin resistance (IR) which lead to the occurrence of type 2 diabetes[4].

Liver biopsy is the gold standard for diagnosing of NAFLD but is expensive and invasive, and cannot be easily adopted worldwide. Thus, several noninvasive imaging methods have emerged such as ultrasonography, computerized tomography (CT), and magnetic resonance imaging (MRI)[5]. However, ultrasonography is subjective and susceptible to many factors. CT is radioactive and MRI is expensive, both of which are not suitable for everyone. Some anthropometric indices used to assess obesity have
been proved to be related with NAFLD. Accumulating evidence has shown that body mass index (BMI), waist-to-hip ratio (WHR) and waist-to-height ratio (WHtR) are useful predictive indicators for the risk of NAFLD[6]. Although the anthropometric measurements are simple and easy to be performed, they are less accurate, operator-dependent and cannot be used to assess the severity of NAFLD. The controlled attenuation parameter (CAP), a novel ultrasound-based technique for measuring fat content in the liver could make up for the above shortcomings[7]. CAP is a promising point-of-care technique which could be used to rapidly and non-invasively assess hepatic steatosis[8]. Furthermore, The Fatty Liver Index (FLI) based on BMI, waist circumference (WC), triglyceride (TG) and gamma-glutamyl-transferase (GGT), as one of several clinical prediction models developed as alternatives for identification of patients with NAFLD, is a simple and accurate predictor of hepatic steatosis in the general population[9].

Thyroid hormones play an important role in the regulation of metabolism, thermogenesis, food intake and fat oxidation. Thyroid dysfunction can lead to obesity and obesity-related complication such as hypertension, dyslipidemia, and IR[10]. And abnormal thyroid function is more common among obese people[11], which may be explained by the increased oxidative stress[12]. There is still controversy about the relationship between different composites of thyroid hormones and NAFLD, with some studies showing that higher free T4 (FT4) levels were associated with lower NAFLD risks and hypothyroidism increased the risk of NAFLD[13], while others demonstrating that free T3 (FT3) levels were positively correlated with NAFLD in euthyroid women[14]. In addition, some researchers have put forward different views from the above that neither FT3 nor FT4 was related to NAFLD[15]. However, most studies were limited to children or the elderly, and thyroid function ranged mostly from subclinical hypothyroidism to the high-normal.

Additionally, thyroid hormones can cause glucose metabolism disorders, increase the blood glucose and lead to diabetes. Several studies have found positive associations between thyroid stimulating hormone (TSH) and IR in hypothyroidism people[16]. However, this association within the normal range of thyroid function is in dispute. Some researchers revealed that homeostasis model of insulin resistance (HOMA-IR) was positively correlated with FT3 and TSH, but negatively related with FT4[17], while others showed the positive association between FT4 and HOMA-IR[18].

In the present study with 88 overweight/obese Chinese adults, we firstly aimed to explore the independent associations of different composites of thyroid-related hormones (FT3, FT4 and TSH) with two indicators of hepatic steatosis (CAP and FLI). Secondly, we also aimed to determine the different association of FT3, FT4 and TSH with insulin resistance which plays the key role linking obesity with metabolic disorders.

**Methods**

**Participants**
A total of 101 overweight/obese participants recruited into this study from November 2018 to October 2020 in the Department of Endocrinology and Diabetes, the First Affiliated Hospital of Xiamen University, Xiamen, China. Overweight/obese participants (defined as below) who aged from 18 to 50 years were eligible. Exclusion criteria for the present study were long-term drinking history, thyroid dysfunction, increased cortisol and presence of known liver disease such as viral or autoimmune hepatitis, and treatment of hepatotoxic medications. A face-to-face interview by using standardized questionnaire was conducted for each participant to collect their living habits, disease history and medicine history. Finally, 13 individuals without thyroid hormone related data were excluded and 88 participants were kept in the present analysis. The study was approved by the Human Research Ethics Committee of the First Affiliated Hospital of Xiamen University (Xiamen, China). Written informed consent was obtained from each participant.

**Anthropometric and laboratory measurements**

Anthropometric measurements were conducted as described in detail previously[19]. Subjects underwent weight, height and waist circumference measurements by using a calibrated scale after removing shoes and heavy clothes. BMI was calculated as the weight in kilograms divided by the square of the height in meters. And overweight and obesity were defined as BMI of 24-27.9kg/m^2 and ≥ 28kg/m^2, respectively[20]. WHtR was calculated as the WC in meters divided by the height in meters. Arterial blood pressure was measured with OMRON electronic sphygmomanometer after sitting for at least 15 minutes. Blood samples were obtained after 12-hour fasting for each subject. Lipid profiles (TG, total cholesterol (TC), and high-density lipoprotein cholesterol (HDL-c)) were determined on a HITACHI 7450 analyzer (HITACHI, Tokyo, Japan). Low-density lipoprotein cholesterol (LDL-C) was calculated by Friedewald’s formula. Fasting plasma glucose (FPG) were measured by the hexokinase method. Serum fasting insulin concentration was measured by electrochemiluminescence immunoassay (Roche Elecsys Insulin Test, Roche Diagnostics, Mannheim, Germany). HOMA-IR was calculated using the formula: fasting serum insulin (mU/L) * fasting plasma glucose (mmol/L) /22.5[21]. FT3, FT4 and TSH levels were measured using electrochemiluminescence immunoassay.

**Hepatic steatosis assessment**

In order to diagnose and assess the severity of hepatic steatosis, CAP was performed using FibroScan® (Echosens, Paris, France) by experienced operators[22]. If transient elastography failed to take ten successful shots, the CAP measurement would be considered invalid[22]. FLI score was calculated using the formula: FLI = e^y/(1 + e^y) * 100, where y = 0.953 * ln (triglycerides, mg/dl) + 0.139 * BMI (kg/m^2) + 0.718 * ln(GGT, U/L) + 0.053 * waist circumference (cm) – 15.745[9].

**Statistical analysis**

Data were presented as the mean ± standard deviation (SD) or as median (inter-quartile range) for continuous variables and number (proportions) for categorical variables. All subjects were stratified by the tertile of FT3. Differences between the three groups were analyzed on continuous variables using one-
way ANOVA for those with normal distributions and Kruskal-Wallis test for those with skewed distributions and on categorical variables using chi-square test.

Pearson's correlation analyses were performed to explore the correlation coefficients between thyroid hormones (FT3, FT4 and TSH) with anthropometric and biochemical features as well as indicators of hepatic steatosis. Multivariable linear regression analyses were performed to explore the independent associations of different composites of thyroid hormones with obesity indices, hepatic steatosis (CAP and FLI) and HOMA-IR as well. BMI, FLI and HOMA-IR did not follow normal distributions and were log-transformed to obtain better approximation of normal distributions. In model 1, no variable was adjusted for. While in model 2, age, sex, occasional drinking, systolic blood pressure (SBP), diastolic blood pressure (DBP) and TSH were adjusted for; and TG, TC, HDL-c and LDL-c were further adjusted in model 3. All p-values were two-sided and p-value < 0.05 was considered statistically significant. All analyses were performed with SPSS version 21.0 software (IBM Corporation).

Results

Of the 88 overweight/obese adults, 24 (27.3%) were male, and the mean (±SD) of age was 30.0±7.2 years old and their median of BMI was 30.0 (kg/m²).

Clinical characteristics of subjects by tertiles of serum FT3 level

Subjects were categorized as three groups based on tertiles of serum FT3 levels (median (inter-quartile range): 4.76 (4.61-4.87), 5.15 (5.10-5.28) and 5.95 (5.58-6.36) pmol/L, respectively). Table 1 shows that, with increasing levels of serum FT3, subjects were more likely to be male and young and had significantly higher levels of BMI, waist circumference, WHtR, systolic BP, fasting insulin, HOMA-IR, FT4 and decreased level of HDL-C. Increased tertiles of serum FT3 were also significantly associated with increased CAP ((295.4±44.1, 290.1 ± 68.2 and 331.7 ± 43.6 (dB/m) for tertile 1-3, respectively, p=0.007) and FLI (47.7 (33.9-60.8), 61.5 (45.1-88.9) and 90.5 (84.5-94.8), respectively, p<0.001) (Figure 1). There were no statistically significant differences in the levels of diastolic BP, FPG, TG, TC, LDL-C and TSH among these three groups of serum FT3.

Correlations of FT3, FT4 and TSH with clinical characteristics

Table 2 shows the Pearson's correlation coefficients of serum FT3, FT4 and TSH with clinical indices of obesity, hepatic steatosis and insulin resistance. For FT3, there were significantly positive correlations with systolic BP, obesity (BMI, WC, WHtR), fasting insulin, insulin resistance (HOMA-IR) and hepatic steatosis (CAP and FLI) as well as negative correlation with age. FT4 was also significantly and positively correlated with systolic BP, obesity (BMI, WC, WHtR) and FLI but not with insulin resistance (HOMA-IR) or CAP. TSH was only significantly correlated with FPG but not any other clinical parameters.

Independent associations of FT3, FT4 and TSH with obesity, insulin resistance and hepatic steatosis
Table 3 shows the adjusted linear regression coefficients ($\beta$) with associated 95% confidence interval (CI) of serum FT3, FT3 and TSH levels for obesity indices (BMI and WHtR), insulin resistance (HOMA-IR) and hepatic steatosis (CAP and FLI) by using the multivariable linear regression analyses with adjustment for potential confounding factors in three different models. In model 1 and model 2, increasing FT3 was significantly associated with increased risks of obesity (BMI and WHtR), insulin resistance (HOMA-IR) and hepatic steatosis (CAP and FLI). In model 3 with full adjustment, the positive associations of serum FT3 with BMI, HOMA-IR and hepatic steatosis (CAP and FLI) were still statistically significant, although the association with WHtR became non-significant.

In model 3 with adjustment for all potential confounding factors, neither FT4 nor TSH was significantly associated with any indicators of obesity (BMI or WHtR), insulin resistance (HOMA-IR) or hepatic steatosis (CAP and FLI).

### Discussion

In the present study of 88 overweight/obese Chinese adults, we found that increased tertiles of serum FT3 were significantly associated with higher levels of BMI, waist circumference, WHtR, fasting insulin, HOMA-IR and hepatic steatosis (CAP and FLI). Pearson correlation analyses also showed that FT3 were significantly and positively correlated with the above parameters. With adjustment for potential confounding factors, multivariable linear regression analyses showed that serum FT3 was independently and positively associated with BMI, HOMA-IR, CAP and FLI. However, neither FT4 nor TSH was independently associated with any indicators of obesity, insulin resistance or hepatic steatosis.

Thyroid hormones play essential roles in maintaining metabolic homeostasis, and thyroid dysfunction is now more common among obese population. In the present study, we found that increasing FT3 levels, but not FT4 or TSH, were significantly associated with increased obesity indices (BMI and WHtR), which was consistent with some previous studies[23, 24]. But there were still some different views on this relationship. Du et al[25] reported an observational study which was conducted in the northernmost region of China and found that no significant association was found between FT3 and components of central obesity (BMI and WHR); but FT4 was negatively, and TSH was positively, correlated with BMI in patients with central obesity. Available evidence as well as ours indicates FT3 plays an important role in the weight regulation. The positive correlation between FT3 and obesity could be explained by the increases of expression and activities of type I indothyronine 5'-deiodinase in adipose tissue, which was an important source of circulating T3[26]. Therefore, elevated FT3, a production of adaptation to obesity, could increase energy expenditure to maintain metabolic balance[27].

Thyroid-related hormones achieve the balance between lipid synthesis and lipid oxidation in different ways, and thereby exerts the effect of lowering lipids[28]. A study conducted in Germany including 3661 subjects without self-reported histories of thyroid or liver diseases showed the inverse relationship between FT4 and NAFLD[29]. Tahara et al[30] found increased TSH within the euthyroid range was an independent risk factor of NAFLD, and might influence the progress of liver fibrosis. Some studies
conducted in euthyroid subjects showed that higher level of FT3 was an independent predictor of NAFLD[31] and that FT3 levels changed with the alteration of NAFLD status[14]. Most above studies used liver ultrasound to assess NAFLD which was subjective. In the current study, NAFLD was evaluated by CAP, which was a newly developed non-invasive and quantitative evaluation method and has been widely used as a first-line assessment for screening fatty liver[22]. In addition, CAP values were closely associated with metabolic syndrome (MetS) and its components including obesity, hypertriglyceridemia, hyperglycemia and hypertension[32]. FLI, as is a simple, accurate and non-invasive approach, has also shown a good capability for discriminating individuals with NAFLD from those without it in a population-based study with 7-year follow up[33]. However, there were few studies to explore the association between thyroid-related hormones with CAP and FLI. Our study found that higher FT3, but not FT4 or TSH, was positively associated with CAP and FLI, which was consistent with previous studies[34, 35].

To further explore the potential mechanism of relationship between thyroid-related hormones with obesity and NAFLD, we analyzed the association between thyroid function and IR, which has been implicated in the pathogenesis of both obesity and NAFLD. In our study, we found FT3 was significantly and positively associated with HOMA-IR, which was consistent with two other studies conducted in euthyroid subjects[18, 36]. The possible mechanism may be that FT3, as a biologically active thyroid hormone, can increase the decomposition of glycogen and promote glucose absorption in small intestinal mucosa to increase the production of endogenous glucose, which could convert to lipid and then deposit in the liver at the effect of high level of serum insulin[37–39]. However, there were still different findings on the relationships of FT3 with obesity, NAFLD and IR. The underlying mechanism were not fully understood. One possible reason may be due to the different study populations, such as the difference in age, sex, race, region, and especially the thyroid functions. Many study populations are accompanied by subclinical hypothyroidism or their TSH is in a normal high stage, and some even have hyperthyroidism or hypothyroidism[40, 41]. Subjects in the present study were middle-aged population with normal thyroid function. Therefore, further researches, including more obese and euthyroid people, will be needed to explore the true relationships of thyroid-related hormones with obesity, NAFLD and IR.

Some limitations in the present study should be recognized. First, the sample size was small and all 88 participants were with NAFLD. Therefore, we might under-estimate the true associations of thyroid-related hormones and obesity, NAFLD and IR, and our results should be confirmed in non-obese and non-NAFLD populations. Secondly, hepatic steatosis was determined by using CAP and FLI, but not liver biopsy, which made the overall sensitivity and specificity of detection of fatty liver compared to liver biopsy were only 80–90%. Thirdly, we cannot determine the temporal sequence between thyroid-related hormones and NAFLD because of the cross-sectional study design. Therefore, a prospective cohort study with larger sample size is needed to address the causal relationships of thyroid-related hormones with hepatic steatosis and IR.

Conclusion
Elevated FT3, but not FT4 or TSH, was associated with increased risk of hepatic steatosis and IR in euthyroid overweight/obese adults. Closely monitoring the FT3 levels should be addressed in terms of preventing hepatic steatosis and IR-related diseases.

**Abbreviations**

NAFLD: nonalcoholic fatty liver disease

T2D: type 2 diabetes

IR: insulin resistance

CT: computerized tomography

MRI: magnetic resonance imaging

BMI: body mass index

WHR: waist-to-hip ratio

WHiR: waist-to-height ratio

CAP: controlled attenuation parameter

FLI: fatty Liver Index

WC: waist circumference

TG: triglyceride

GGT: gamma-glutamyl-transferase

FT4: free thyroxine

FT3: free triiodothyronine

TSH: thyroid stimulating hormone

HOMA-IR: homeostasis model of insulin resistance

TC: total cholesterol

HDL-c: high-density lipoprotein cholesterol

LDL-c: low-density lipoprotein cholesterol

FPG: fasting plasma glucose
SD: standard deviation
SBP: systolic blood pressure
DBP: diastolic blood pressure
CI: confidence interval
MetS: metabolic syndrome

Declarations

Author Contributions

The study concept and design were framed by CL and ZL. FY, JY, YC, XZ and ZC collected data. DM, JZ and BH conducted the statistical data analysis and drafted the manuscript. ML contributed to discussion and revision. All authors read and approved the final manuscript.

Funding Information

CL was founded by Natural Science Foundation of China grant (No. 81870611), Natural Science Foundation of Fujian Province (NO. 2020J011242) and Open project of State Key Laboratory of Cellular Stress Biology, Xiamen University (No. SKLCSB2019KF004). ZL was founded by the National Key R&D Program of China grant no: 2017YFC0907100.

Conflict of Interest

The authors declare that they have no conflict of interest.

Ethical Approval and consent to participant

The study was approved by the Human Research Ethics Committee of the First Affiliated Hospital of Xiamen University (Xiamen, China). Written informed consent was obtained from each participant. All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the Helsinki declaration and its later amendments or comparable ethical standards.

Availability of data and material

The data used to support the findings of this study are available from the corresponding author upon reasonable request.

Consent to publication

Informed consent was obtained from all individual participants included in the study.
Acknowledgements

We are grateful to all the subjects for their participation.

References

1. Leoni S, Tovoli F, Napoli L, Serio I, Ferri S, Bolondi L. Current guidelines for the management of non-alcoholic fatty liver disease: A systematic review with comparative analysis. World journal of gastroenterology. 2018 Aug 14;24(30):3361-73.
2. Fan JG, Kim SU, Wong VW. New trends on obesity and NAFLD in Asia. Journal of hepatology. 2017 Oct,67(4):862-73.
3. Atri A, Jiwanmall SA, Nandyal MB, et al. The Prevalence and Predictors of Non-alcoholic Fatty Liver Disease in Morbidly Obese Women - A Cross-sectional Study from Southern India. European endocrinology. 2020 Oct,16(2):152-55.
4. Chait A, den Hartigh LJ. Adipose Tissue Distribution, Inflammation and Its Metabolic Consequences, Including Diabetes and Cardiovascular Disease. Frontiers in cardiovascular medicine. 2020,7:22.
5. Zhang YN, Fowler KJ, Hamilton G, et al. Liver fat imaging—a clinical overview of ultrasound, CT, and MR imaging. The British journal of radiology. 2018 Sep,91(1089):20170959.
6. Lin M-S, Lin T-H, Guo S-E, et al. Waist-to-height ratio is a useful index for nonalcoholic fatty liver disease in children and adolescents: a secondary data analysis. BMC Public Health. 2017,17(1).
7. Boursier J, Cales P. Controlled attenuation parameter (CAP): a new device for fast evaluation of liver fat? Liver Int. 2012 Jul,32(6):875-7.
8. Castera L, Friedrich-Rust M, Loomba R. Noninvasive Assessment of Liver Disease in Patients With Nonalcoholic Fatty Liver Disease. Gastroenterology. 2019 Apr,156(5):1264-81 e4.
9. Bedogni G, Bellentani S, Miglioli L, et al. The Fatty Liver Index: a simple and accurate predictor of hepatic steatosis in the general population. BMC Gastroenterol. 2006 Nov 2,6:33.
10. Hamlaoui ML, Ayachi A, Dekaken A, Gouri A. Relationship of metabolic syndrome and its components with thyroid dysfunction in Algerian patients. Diabetes & metabolic syndrome. 2018 Jan-Mar,12(1):1-4.
11. Dahl M, Ohrt JD, Fonvig CE, et al. Subclinical Hypothyroidism in Danish Lean and Obese Children and Adolescents. Journal of clinical research in pediatric endocrinology. 2017 Mar 1,9(1):8-16.
12. D’Adamo E, De Leonibus C, Giannini C, et al. Thyroid dysfunction in obese pre-pubertal children: oxidative stress as a potential pathogenetic mechanism. Free radical research. 2012 Mar,46(3):303-9.
13. Bano A, Chaker L, Plompen EP, et al. Thyroid Function and the Risk of Nonalcoholic Fatty Liver Disease: The Rotterdam Study. J Clin Endocrinol Metab. 2016 Aug,101(8):3204-11.
14. Chen P, Hou X, Wei L, et al. Free triiodothyronine is associated with the occurrence and remission of nonalcoholic fatty liver disease in euthyroid women. Eur J Clin Invest. 2019 Apr,49(4):e13070.
15. Torun E, Ozgen IT, Gokce S, Aydin S, Cesur Y. Thyroid hormone levels in obese children and adolescents with non-alcoholic fatty liver disease. J Clin Res Pediatr Endocrinol. 2014,6(1):34-9.

16. Singh BM, Goswami B, Mallika V. Association between insulin resistance and hypothyroidism in females attending a tertiary care hospital. Indian journal of clinical biochemistry : IJCB. 2010 Apr,25(2):141-5.

17. Hainer V, Zamrazilová H, Aldhoon Hainerová I. [Are the thyroid hormones and thyrotropin associated with cardiometabolic risks and insulin resistance even in euthyroid subjects?] Vnitrni lekarstvi. 2016 Fall,62(9 Suppl 3):63-67.

18. Lambadiari V, Mitrou P, Maratou E, et al. Thyroid hormones are positively associated with insulin resistance early in the development of type 2 diabetes. Endocrine. 2011 Feb,39(1):28-32.

19. Du C, He C, Dong L, et al. Associations of apnea hypopnea index and educational attainments with microvascular complications in patients with T2DM. Endocrine. 2020 Feb,67(2):363-73.

20. Zhou BF. Predictive values of body mass index and waist circumference for risk factors of certain related diseases in Chinese adults–study on optimal cut-off points of body mass index and waist circumference in Chinese adults. Biomedical and environmental sciences : BES. 2002 Mar,15(1):83-96.

21. Ascaso JF, Pardo S, Real JT, Lorente RI, Priego A, Carmen R. Diagnosing insulin resistance by simple quantitative methods in subjects with normal glucose metabolism. Diabetes Care. 2003 Dec,26(12):3320-5.

22. Karlas T, Petroff D, Sasso M, et al. Individual patient data meta-analysis of controlled attenuation parameter (CAP) technology for assessing steatosis. J Hepatol. 2017 May,66(5):1022-30.

23. Ren R, Jiang X, Zhang X, et al. Association between thyroid hormones and body fat in euthyroid subjects. Clin Endocrinol (Oxf). 2014 Apr,80(4):585-90.

24. Roef GL, Rietzschel ER, Van Daele CM, et al. Triiodothyronine and free thyroxine levels are differentially associated with metabolic profile and adiposity-related cardiovascular risk markers in euthyroid middle-aged subjects. Thyroid. 2014 Feb,24(2):223-31.

25. Du FM, Kuang HY, Duan BH, Liu DN, Yu XY. Effects of thyroid hormone and depression on common components of central obesity. The Journal of international medical research. 2019 Jul,47(7):3040-49.

26. Ortega FJ, Jílková ZM, Moreno-Navarrete JM, Pavelka S, Rodriguez-Hermosa JI, Kopeck Ygrave J, et al. Type I iodothyronine 5'-deiodinase mRNA and activity is increased in adipose tissue of obese subjects. International journal of obesity (2005). 2012 Feb,36(2):320-4.

27. Nam JS, Cho M, Park JS, et al. Triiodothyronine level predicts visceral obesity and atherosclerosis in euthyroid, overweight and obese subjects: T3 and visceral obesity. Obesity research & clinical practice. 2010 Oct-Dec,4(4):e247-342.

28. Cordeiro A, Souza LL, Einicker-Lamas M, Pazos-Moura CC. Non-classic thyroid hormone signalling involved in hepatic lipid metabolism. The Journal of endocrinology. 2013 Mar,216(3):R47-57.
29. Ittermann T, Haring R, Wallaschofski H, et al. Inverse association between serum free thyroxine levels and hepatic steatosis: results from the Study of Health in Pomerania. Thyroid. 2012 Jun,22(6):568-74.

30. Tahara K, Akahane T, Namisaki T, et al. Thyroid-stimulating hormone is an independent risk factor of non-alcoholic fatty liver disease. JGH Open. 2020 Jun,4(3):400-04.

31. Liu G, Zheng X, Guan L, et al. Free triiodothyronine levels are positively associated with non-alcoholic fatty liver disease in euthyroid middle-aged subjects. Endocr Res. 2015,40(4):188-93.

32. Hu YY, Dong NL, Qu Q, Zhao XF, Yang HJ. The correlation between controlled attenuation parameter and metabolic syndrome and its components in middle-aged and elderly nonalcoholic fatty liver disease patients. Medicine (Baltimore). 2018 Oct,97(43):e12931.

33. Motamed N, Faraji AH, Khonsari MR, et al. Fatty liver index (FLI) and prediction of new cases of non-alcoholic fatty liver disease: A population-based study of northern Iran. Clin Nutr. 2020 Feb,39(2):468-74.

34. Liu Y, Wang W, Yu X, Qi X. Thyroid Function and Risk of Non-Alcoholic Fatty Liver Disease in Euthyroid Subjects. Ann Hepatol. 2018 Aug 24,17(5):779-88.

35. Borges-Canha M, Neves JS, Mendonça F, et al. Thyroid Function and the Risk of Non-Alcoholic Fatty Liver Disease in Morbid Obesity. Frontiers in endocrinology. 2020,11:572128.

36. Kwon H, Cho JH, Lee DY, et al. Association between thyroid hormone levels, body composition and insulin resistance in euthyroid subjects with normal thyroid ultrasound: The Kangbuk Samsung Health Study. Clin Endocrinol (Oxf). 2018 Nov,89(5):649-55.

37. Gathercole LL, Morgan SA, Bujalska IJ, Hauton D, Stewart PM, Tomlinson JW. Regulation of lipogenesis by glucocorticoids and insulin in human adipose tissue. PLoS One. 2011,6(10):e26223.

38. Rui L. Energy metabolism in the liver. Comprehensive Physiology. 2014 Jan,4(1):177-97.

39. Smith GI, Shankaran M, Yoshino M, et al. Insulin resistance drives hepatic de novo lipogenesis in nonalcoholic fatty liver disease. The Journal of clinical investigation. 2020 Mar,2130(3):1453-60.

40. van den Berg EH, van Tienhoven-Wind LJ, Amini M, et al. Higher free triiodothyronine is associated with non-alcoholic fatty liver disease in euthyroid subjects: the Lifelines Cohort Study. Metabolism. 2017 Feb,67:62-71.

41. Kim D, Kim W, Joo SK, Bae JM, Kim JH, Ahmed A. Subclinical Hypothyroidism and Low-Normal Thyroid Function Are Associated With Nonalcoholic Steatohepatitis and Fibrosis. Clin Gastroenterol Hepatol. 2018 Jan,16(1):123-31 e1.

Tables

Table 1. Characteristics of subjects by tertiles of free triiodothyronine level.
| Variables                      | Tertile 1     | Tertile 2     | Tertile 3     | Total      | P value |
|-------------------------------|---------------|---------------|---------------|------------|---------|
| N (%)                         | 29 (33.0%)    | 30 (34.0%)    | 29 (33.0%)    | 88 (100.0%)| <0.001* |
| Male gender                   | 2 (6.9%)      | 5 (16.7%)     | 17 (58.6%)    | 24 (27.3%) | 0.024*  |
| Age (years)                   | 32.2 ± 7.2    | 29.3 ± 7.4    | 27.2 ± 5.8    | 30.0 ± 7.2 | 0.024*  |
| Ever drinking (n, %)          | 1 (3.4%)      | 2 (6.7%)      | 6 (20.7%)     | 9 (10.2%)  | 0.070   |
| BMI (kg/m²)                   | 27.9 (26.3-31.3) | 29.4 (27.8-32.5) | 33.5 (30.6-36.5) | 30.0 (27.7-33.4) | <0.001* |
| Waist circumference (cm)      | 91.3 ± 8.4    | 96.0 ± 10.1   | 106.1 ± 11.8  | 97.2 ± 11.8| <0.001* |
| WHtR                          | 0.56 ± 0.04   | 0.59 ± 0.05   | 0.63 ± 0.07   | 0.59 ± 0.06| <0.001* |
| Systolic blood pressure (mmHg)| 118.5 ± 10.8  | 121.0 ± 11.3  | 128.3 ± 17.5  | 122.6 ± 14.0| 0.019*  |
| Diastolic blood pressure (mmHg)| 80.5 ± 8.7   | 80.9 ± 9.1    | 80.9 ± 12.3   | 80.8 ± 10.0| 0.986   |
| FPG (mmol/L)                  | 5.06 (4.60-5.42) | 4.86 (4.61-5.42) | 5.14 (4.56-5.31) | 4.97 (4.59-5.35) | 0.813   |
| Fasting insulin (pmol/L)      | 101.8 (82.7-138.2) | 120.4 (91.8-158.6) | 162.7 (122.8-222.9) | 128.3 (91.2-180.9) | 0.002*  |
| HOMA-IR                       | 3.25 (2.62-4.55) | 3.96 (3.03-5.52) | 5.20 (3.83-6.56) | 4.03 (3.06-5.85) | 0.002*  |
| Triglyceride (mmol/L)         | 1.36 (1.14-2.26) | 1.64 (1.29-2.15) | 1.84 (1.58-2.82) | 1.63 (1.27-2.54) | 0.054   |
| Total cholesterol (mmol/L)    | 5.27 ± 1.05   | 4.96 ± 0.84   | 5.14 ± 0.94   | 5.14 ± 0.96 | 0.481   |
| HDL-cholesterol (mmol/L)      | 1.33 ± 0.29   | 1.15 ± 0.27   | 1.23 ± 0.23   | 1.23 ± 0.27 | 0.039*  |
| LDL-cholesterol (mmol/L)      | 3.17 ± 0.74   | 2.96 ± 0.71   | 3.08 ± 0.84   | 3.08 ± 0.78 | 0.600   |
| FT3 (pmol/L)                  | 4.76 (4.61-4.87) | 5.15 (5.10-5.28) | 5.95 (5.58-6.36) | 5.15 (4.87-5.61) | <0.001* |
| FT4 (pmol/L)                  | 15.75 ± 2.41  | 17.47 ± 2.13  | 17.94 ± 2.57  | 17.06 ± 2.53| 0.002*  |
| TSH (mIU/L)                   | 2.50 (1.41-3.31) | 2.23 (1.52-2.90) | 2.09 (1.40-2.80) | 2.24 (1.48-2.98) | 0.573   |
| FLI score                     | 47.7 (33.9-60.8) | 61.5 (45.1-88.9) | 90.5 (84.5-94.8) | 69.3 (46.0-90.9) | <0.001* |
| CAP (dB/m)                    | 295.4 ± 44.1  | 290.1 ± 68.2  | 331.7 ± 43.6  | 305.0 ± 55.0| 0.007*  |
Data were presented as mean ± SD or median (interquartile ranges) for continuous variables, and numbers (proportions) for categorical variables.

Abbreviations: SBP, systolic pressure; DBP, diastolic pressure; WC, waist circumference; BMI, body mass index; WHtR, Waist-To-Height Ratio; FPG, fasting plasma glucose; HOMA-IR homeostatic model assessment of insulin resistance; TC, total cholesterol; TG, triglycerides; HDL-c, high density lipoprotein cholesterol; LDL-c, low density lipoprotein cholesterol; FT3, free triiodothyronine; FT4, free thyroxine; TSH, thyroid stimulating hormone; FLI, Fatty Liver Index; CAP, controlled attenuation parameter.

Table 2. Pearson’s correlation coefficients of free triodothyronine, free thyroxine and thyroid stimulating hormone with clinical features and hepatic steatosis.

| Variables   | FT3       |   | FT4       |   | TSH       |   |
|-------------|-----------|---|-----------|---|-----------|---|
|             | r         | p-value | r         | p-value | r         | p-value |
| Age (years) | -0.271    | 0.011*  | -0.147    | 0.171   | -0.199    | 0.063   |
| SBP (mmHg)  | 0.247     | 0.021*  | 0.258     | 0.016*  | 0.027     | 0.806   |
| DBP (mmHg)  | -0.022    | 0.841   | 0.121     | 0.266   | 0.095     | 0.382   |
| WC (cm)     | 0.487     | <0.001* | 0.315     | 0.003*  | 0.007     | 0.946   |
| BMI (kg/m²) | 0.5       | <0.001* | 0.289     | 0.006*  | -0.008    | 0.938   |
| WHtR        | 0.405     | <0.001* | 0.228     | 0.035*  | 0.003     | 0.979   |
| FPG (mmol/L)| -0.04     | 0.712   | -0.157    | 0.145   | -0.239    | 0.025*  |
| Fins(pmol/L)| 0.376     | <0.001* | -0.002    | 0.984   | 0.069     | 0.526   |
| HOMA-IR     | 0.366     | <0.001* | -0.034    | 0.757   | -0.021    | 0.849   |
| TC (mmol/L) | -0.039    | 0.722   | -0.056    | 0.611   | -0.121    | 0.273   |
| TG (mmol/L) | 0.218     | 0.047*  | 0.173     | 0.116   | 0.014     | 0.900   |
| HDL-c (mmol/L) | -0.15 | 0.173 | -0.052 | 0.641 | 0.132 | 0.232 |
| LDL-c (mmol/L) | -0.019 | 0.865 | -0.066 | 0.553 | -0.109 | 0.325 |
| TSH (mIU/L) | -0.081    | 0.454   | -0.158    | 0.142   | —         | —       |
| FLI score   | 0.492     | <0.001* | 0.322     | 0.003*  | -0.03     | 0.785   |
| CAP (dB/m)  | 0.278     | 0.009*  | 0.072     | 0.504   | 0.037     | 0.731   |

* p<0.05
Abbreviations: SBP, systolic pressure; DBP, diastolic pressure; WC, waist circumference; BMI, body mass index; WHtR, Waist-To-Height Ratio; FPG, fasting plasma glucose; Fins, Fasting Insulin; HOMA-IR, homeostatic model assessment of insulin resistance; TC, total cholesterol; TG, triglycerides; HDL-c, high density lipoprotein cholesterol; LDL-c, low density lipoprotein cholesterol; TSH, thyroid stimulating hormone; FLI, Fatty Liver Index; CAP, controlled attenuation parameter; FT3, free triiodothyronine; FT4, free thyroxine; TSH, thyroid stimulating hormone;

Table 3. Multiple linear regression analyses of FT3, FT4 and TSH with obesity indices, hepatic steatosis and HOMA-IR.

| Variables | BMI (log-transformed) | WHtR | CAP | FLI score (log-transformed) | HOMA-IR (log-transformed) |
|-----------|----------------------|------|-----|-----------------------------|--------------------------|
|           | β (95%CI)            | p-value | β (95%CI) | p-value | β (95%CI) | p-value | β (95%CI) | p-value |
| FT3       |                      |       |     |                             |                          |
| Model 1   | 0.044 (0.027-0.061)  | <0.001 | 0.038 (0.017-0.059) | 0.001** | 25.11 (7.14-44.07) | 0.001** | 0.157 (0.083-0.231) | <0.001** | 0.134 (0.064-0.204) | <0.001** |
| Model 2   | 0.028 (0.009-0.046)  | 0.005** | 0.027 (0.002-0.052) | 0.034** | 22.36 (9.09-44.63) | 0.049** | 0.093 (0.008-0.176) | 0.032** | 0.090 (0.011-0.170) | 0.011** |
| Model 3   | 0.024 (0.004-0.045)  | 0.020** | 0.021 (-0.004-0.049) | 0.104 | 25.45 (7.29-48.31) | 0.001** | 0.121 (0.049-0.192) | 0.001** | 0.091 (0.007-0.174) | 0.034** |
| FT4       |                      |       |     |                             |                          |
| Model 1   | 0.007 (0.002-0.012)  | 0.004** | 0.005 (0.000-0.010) | 0.057 | 1.370 (3.369-4.579) | 0.567 | 0.015 (-0.005-0.035) | 0.143 | -0.002 (-0.020-0.016) | 0.841 |
| Model 2   | 0.004 (-0.001-0.010) | 0.092 | 0.002 (-0.003-0.007) | 0.397 | -0.383 (-5.371-4.605) | 0.886 | 0.003 (-0.017-0.023) | 0.784 | -0.013 (-0.031-0.005) | 0.167 |
| Model 3   | 0.004 (-0.001-0.010) | 0.126 | 0.002 (-0.004-0.008) | 0.185 | -1.176 (-6.939-4.656) | 0.685 | 0.007 (-0.011-0.025) | 0.436 | -0.016 (-0.036-0.004) | 0.125 |
| TSH       |                      |       |     |                             |                          |
| Model 1   | -0.001(-0.009-0.007) | 0.929 | -0.002 (-0.012-0.007) | 0.625 | 1.655 (-7.107-10.417) | 0.708 | -0.004 (-0.039-0.032) | 0.832 | 0.001 (-0.003-0.005) | 0.962 |
| Model 2   | -0.001(-0.009-0.007) | 0.710 | -0.004 (-0.013-0.005) | 0.431 | 2.333 (-6.367-11.032) | 0.595 | -0.003 (-0.034-0.028) | 0.870 | 0.000 (-0.015-0.008) | 0.868 |
| Model 3   | -0.001(-0.009-0.007) | 0.708 | -0.004 (-0.014-0.005) | 0.329 | 3.206 (-6.003-12.415) | 0.460 | 0.003 (-0.026-0.035) | 0.854 | 0.002 (-0.030-0.035) | 0.893 |

* p<0.05

Model 1: No adjustment.
Model 2: Adjustment for age, sex, smoking status, alcohol consumption, BMI, WHtR and TSH.
Model 3: Adjustment for age, sex, smoking status, alcohol consumption, BMI, WHtR, TSH, TC and HDL-c.

Abbreviations: BMI, body mass index; WHR, Waist-To-Height Ratio; HOMA-IR, homeostatic model assessment of insulin resistance; FLI, Fatty Liver Index, CAP, controlled attenuation parameter; FT3, free triiodothyronine; FT4, free thyroxine; TSH, thyroid stimulating hormone;

Figures

Image not available with this version

Figure 1

Distributions of BMI (log-transformed), WHtR, CAP, FLI and HOMA-IR (log-transformed) stratified by FT3 tertiles.